Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cell-based immunotherapy against gliomas: from bench to bedside.

Literature DB >> 23648695

Cell-based immunotherapy against gliomas: from bench to bedside.

M Sarah S Bovenberg¹, M Hannah Degeling, Bakhos A Tannous.

Abstract

Glioblastoma (GBM) comprises 51% of all gliomas and is the most malignant form of brain tumors with a median survival of 18-21 months. Standard-of-care treatment includes maximal surgical resection of the tumor mass in combination with radiation and chemotherapy. However, as the poor survival rate indicates, these treatments have not been effective in preventing disease progression. Cellular immunotherapy is currently being explored as therapeutic approach to treat malignant brain tumors. In this review, we discuss advances in active, passive, and vaccine-based immunotherapeutic strategies for gliomas both at the bench and in the clinic.

Entities: Disease

Mesh：

Year: 2013 PMID： 23648695 PMCID： PMC3702108 DOI： 10.1038/mt.2013.80

Source DB: PubMed Journal: Mol Ther ISSN： 1525-0016 Impact factor: 11.454

67 in total

1. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells.

Authors: A Rodriguez; A Regnault; M Kleijmeer; P Ricciardi-Castagnoli; S Amigorena
Journal: Nat Cell Biol Date: 1999-10 Impact factor: 28.824

2. Dermal substitutes do well on dura: comparison of split skin grafting +/- artificial dermis for reconstruction of full-thickness calvarial defects.

Authors: R A J Wain; S H A Shah; K Senarath-Yapa; J K G Laitung
Journal: Clin Plast Surg Date: 2012-01 Impact factor: 2.017

3. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.

Authors: Alexia Ghazi; Aidin Ashoori; Patrick J Hanley; Vita S Brawley; Donald R Shaffer; Yvonne Kew; Suzanne Z Powell; Robert Grossman; Zakaria Grada; Michael E Scheurer; Meenakshi Hegde; Ann M Leen; Catherine M Bollard; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk; Nabil Ahmed
Journal: J Immunother Date: 2012 Feb-Mar Impact factor: 4.456

Review 4. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Authors: Paul J Tacken; I Jolanda M de Vries; Ruurd Torensma; Carl G Figdor
Journal: Nat Rev Immunol Date: 2007-10 Impact factor: 53.106

5. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas.

Authors: D W Andrews; M Resnicoff; A E Flanders; L Kenyon; M Curtis; G Merli; R Baserga; G Iliakis; R D Aiken
Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544

Review 6. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.

Authors: Giulia Mesiano; Maja Todorovic; Loretta Gammaitoni; Valeria Leuci; Lidia Giraudo Diego; Fabrizio Carnevale-Schianca; Franca Fagioli; Wanda Piacibello; Massimo Aglietta; Dario Sangiolo
Journal: Expert Opin Biol Ther Date: 2012-04-14 Impact factor: 4.388

7. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

Authors: Stuart A Grossman; Xiaobu Ye; Steven Piantadosi; Serena Desideri; Louis B Nabors; Myrna Rosenfeld; Joy Fisher
Journal: Clin Cancer Res Date: 2010-04-06 Impact factor: 12.531

8. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy.

Authors: G Elizabeth Pluhar; Patrick T Grogan; Charlie Seiler; Michelle Goulart; Karen S Santacruz; Cathy Carlson; Wei Chen; Mike R Olin; Pedro R Lowenstein; Maria G Castro; Stephen J Haines; John R Ohlfest
Journal: Vaccine Date: 2010-03-01 Impact factor: 3.641

9. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.

Authors: Sumia Ali; Gwendalyn D King; James F Curtin; Marianela Candolfi; Weidong Xiong; Chunyan Liu; Mariana Puntel; Queng Cheng; Jesus Prieto; Antoni Ribas; Jerzy Kupiec-Weglinski; Nico van Rooijen; Hans Lassmann; Pedro R Lowenstein; Maria G Castro
Journal: Cancer Res Date: 2005-08-15 Impact factor: 12.701

10. Conditional probability of long-term survival in glioblastoma: a population-based analysis.

Authors: Derek R Johnson; Daniel J Ma; Jan C Buckner; Julie E Hammack
Journal: Cancer Date: 2012-05-08 Impact factor: 6.860

11 in total

1. Judging a tumor cell by its cover: a matter of mitochondrial contact sites.

Authors: Sowmya Lakshminarayanan; Luca Scorrano
Journal: EMBO J Date: 2017-03-16 Impact factor: 11.598

2. Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma.

Authors: Wenjuan Ma; Yanling Wang; Rongxin Zhang; Fan Yang; Duo Zhang; Menggui Huang; Lin Zhang; Jay F Dorsey; Zev A Binder; Donald M O'Rourke; Joseph A Fraietta; Yanqing Gong; Yi Fan
Journal: Nat Cancer Date: 2020-11-30

Review 3. The biology and mathematical modelling of glioma invasion: a review.

Authors: J C L Alfonso; K Talkenberger; M Seifert; B Klink; A Hawkins-Daarud; K R Swanson; H Hatzikirou; A Deutsch
Journal: J R Soc Interface Date: 2017-11 Impact factor: 4.118

4. Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40.

Authors: Fan Yang; Zhenqiang He; Hao Duan; Duo Zhang; Juehui Li; Huijuan Yang; Jay F Dorsey; Wei Zou; S Ali Nabavizadeh; Stephen J Bagley; Kalil Abdullah; Steven Brem; Lin Zhang; Xiaowei Xu; Katelyn T Byrne; Robert H Vonderheide; Yanqing Gong; Yi Fan
Journal: Nat Commun Date: 2021-06-08 Impact factor: 14.919

Review 5. The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.

Authors: Semer Maksoud
Journal: Mol Neurobiol Date: 2021-03-04 Impact factor: 5.682